

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10571991
Filing Date	2006-03-15
First Named Inventor	Bernard Barlaam
Art Unit	1624
Examiner Name	Douglas M. Willis
Attorney Docket Number	09963.0008

<b>U.S.PATENTS</b>						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5576322		1996-11-19	Takase et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

**Add**

<b>U.S.PATENT APPLICATION PUBLICATIONS</b>						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20040053972	A1	2004-03-18	Nara et al.	
	2	20040192664	A1	2004-09-30	Kunz et al.	
	3	20040198997	A1	2004-10-07	Scholz et al.	
	4	20050130995	A1	2005-06-16	Nishino et al.	
	5	20050148607	A1	2005-07-07	Suzuki et al.	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>		Application Number		10571991	
		Filing Date		2006-03-15	
		First Named Inventor		Bernard Barlaam	
		Art Unit		1624	
		Examiner Name		Douglas M. Willis	
		Attorney Docket Number		09963.0008	

	6	20060167026	A1	2006-07-27	Nawa et al.	
	7	20060188501	A1	2006-08-24	Homma et al.	
	8	20090312313	A1	2009-12-17	Shimizu et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

#### FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	2001/19788	WO	A2	2001-03-22	COR Therapeutics, Inc.	(Submitted in 3 parts)	<input type="checkbox"/>
	2	2001/21160	WO	A2	2001-03-29	Axxima Pharmaceuticals Aktiengesellschaft		<input type="checkbox"/>
	3	2001/32155	WO	A2	2001-05-10	The University of Manchester		<input type="checkbox"/>
	4	2001/64642	WO	A2	2001-09-07	COR Therapeutics, Inc.	(Submitted in 3 parts)	<input type="checkbox"/>
	5	2002/05791	WO	A2	2002-01-24	Pharmacia & Upjohn S.P.A.		<input type="checkbox"/>
	6	2002/17712	WO	A2	2002-03-07	FMC Corporation	(Submitted in 2 parts)	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <b>( Not for submission under 37 CFR 1.99)</b>		Application Number		10571991	
		Filing Date		2006-03-15	
		First Named Inventor		Bernard Barlaam	
		Art Unit		1624	
		Examiner Name		Douglas M. Willis	
		Attorney Docket Number		09963.0008	

	7	2002/20020	WO	A1	2002-03-14	Pharmacia & Upjohn, S.P.A.		<input type="checkbox"/>
	8	2002/30358	WO	A2	2002-04-18	Tularik, Inc.		<input type="checkbox"/>
	9	2003/031406	WO	A2	2003-04-17	IRM LLC		<input type="checkbox"/>
	10	2003/097086	WO	A2	2003-11-27	Technische Universitat Munchen	(Submitted in 2 parts)	<input type="checkbox"/>
	11	2003/097615	WO	A1	2003-11-27	Scios, Inc.	(Submitted in 2 parts)	<input type="checkbox"/>
	12	2003/099276	WO	A1	2003-12-04	Bristol-Myers Squibb Company	(Submitted in 7 parts)	<input type="checkbox"/>
	13	2004/010929	WO	A2	2004-02-05	Scios, Inc.		<input type="checkbox"/>
	14	2004/072038	WO	A1	2004-08-26	Vertex Pharmaceuticals, Inc.		<input type="checkbox"/>
	15	2004/085385	WO	A2	2004-10-07	Schering Corporation		<input type="checkbox"/>
	16	2004/096224	WO	A2	2004-11-11	Boehringer Ingelheim International GmbH		<input type="checkbox"/>
	17	2005/001053	WO	A2	2005-01-06	Waksal et al.		<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>	Application Number		10571991	
	Filing Date		2006-03-15	
	First Named Inventor		Bernard Barlaam	
	Art Unit		1624	
	Examiner Name		Douglas M. Willis	
	Attorney Docket Number		09963.0008	

	18	2005/003325	WO	A2	2005-01-13	Dana Farber Cancer Institute		<input type="checkbox"/>
	19	2005/016347	WO	A1	2005-02-24	Pfizer Products, Inc.		<input type="checkbox"/>
	20	2005/030140	WO	A2	2005-04-07	Ex-Elixis, Inc.	(Submitted in 4 parts)	<input type="checkbox"/>
	21	2000/72849	WO	A1	2000-12-07	Hadasit Medical Research Services and Development		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

#### NON-PATENT LITERATURE DOCUMENTS

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	ALFEREZ ET AL. "Inhibiting Signaling by erbB Receptor Tyrosine Kinases with AZD8931, a Potent Reversible small Molecule Inhibitor, Reduces Intestinal Adenoma Formation in the ApcMin/+ Mouse Model". EORTC-NCI-AACR (2010), Abstract 471	<input type="checkbox"/>
	2	ALFEREZ ET AL. "Inhibiting Signaling by erbB Receptor Tyrosine Kinases with AZD8931, a Potent Reversible small Molecule Inhibitor, Reduces Intestinal Adenoma Formation in the ApcMin/+ Mouse Model". EORTC-NCI-AACR (2010), Poster	<input type="checkbox"/>
	3	BLOWERS "AZD8931". IASLC ANNUAL TARGETED THERAPIES OF THE TREATMENT OF LUNG CANCER MEETING (2011), Santa Monica, CA, PowerPoint Presentation	<input type="checkbox"/>
	4	CRISTOFANILLI ET AL. "Exploratory Subset Analysis According to Prior Endocrine Treatment of Two Randomized Phase II Trials Comparing Gefitinib (G) with Placebo (P) in Combination with Tamoxifen (T) or Anastrozole (A) in Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (MBC)". J CLIN. ONCOL. (2009), Vol. 27, 15s, Abstract 1014	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>	Application Number	10571991
	Filing Date	2006-03-15
	First Named Inventor	Bernard Barlaam
	Art Unit	1624
	Examiner Name	Douglas M. Willis
	Attorney Docket Number	09963.0008

5	HICKINSON ET AL. "AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2) and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer". CLIN. CANCER RES. (2010), Vol. 16, No. 4, 1159-1169	<input type="checkbox"/>
6	KEILHOLZ ET AL. "Phase I Dose-Finding Study of Monotherapy with AZD8931, an Inhibitor of erbB1, 2 and 3 Signaling, in Patients with Advanced Solid Tumors". J CLIN ONCOL. (2011), Vol. 29, Abstract 3097	<input type="checkbox"/>
7	KEILHOLZ ET AL. "Phase I Dose-Finding Study of Monotherapy with AZD8931, an Inhibitor of erbB1, 2 and 3 Signaling, in Patients with Advanced Solid Tumors". ASCO (2011), Poster	<input type="checkbox"/>
8	KLINOWSKA ET AL. "AZD8931, an Equipotent, Reversible Inhibitor of erbB1, erbB2 and erbB3 Receptor Signaling: Characterisation of Pharmacological Profile". EUROPEAN JOURNAL OF CANCER SUPPLEMENTS (2009), Vol. 7, No. 2, 127	<input type="checkbox"/>
9	LOPEZ-MARTIN ET AL. "Phase I Dose-Finding Study of AZD8931, an Inhibitor of erbB1, 2 and 3 Receptor Signaling, in Combination with Paclitaxel". J CLIN. ONCOL. (2011), Vol. 29, Abstract 3105	<input type="checkbox"/>
10	LOPEZ-MARTIN ET AL. "Phase I Dose-Finding Study of AZD8931, an Inhibitor of erbB1, 2 and 3 Receptor Signaling, in Combination with Paclitaxel". ASCO (2011), Poster	<input type="checkbox"/>
11	MARSHALL ET AL. "Evaluation of AZD8931, an Equipotent Inhibitor of erbB1, erbB2 and erbB3 Receptor Signaling, on Ligand Stimulated Breast Cancer Cell Lines with Differing Levels of erbB2 Expression". SABCS (2009), Abstract 5059	<input type="checkbox"/>
12	NORMANNO ET AL. "Target-based therapies in breast cancer: current status and future perspectives". ENDOCR RELAT CANCER (2009), Vol. 16(3): 675-702	<input type="checkbox"/>
13	SPEAKE ET AL. "Characterization of AZD8931, a Potent Reversible Small Molecule Inhibitor Against Epidermal Growth Factor Receptor (EGFR), Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) and 3 (HER3) with a Unique and Balanced Pharmacological Profile". J CLIN. ONCOL. (2009), Vol. 27, 15s, Abstract 11072	<input type="checkbox"/>
14	United States Court of Appeals for the Federal Circuit, Genetics Institute, LLC v. Novartis Vaccines and Diagnostics, Inc., 2010-124; Appeal from the USDC for the District of Delaware in Case No. 08-CV-0290, Judge Sue L. Robinson, Decided August 23, 2011	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button    [Add](#)

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <b>( Not for submission under 37 CFR 1.99)</b>	Application Number	10571991
	Filing Date	2006-03-15
	First Named Inventor	Bernard Barlaam
	Art Unit	1624
	Examiner Name	Douglas M. Willis
	Attorney Docket Number	09963.0008

#### EXAMINER SIGNATURE

Examiner Signature	/Douglas Willis/	Date Considered	12/19/2011
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.